Sitagliptin as an Add-on Therapy to Other Glucose-lowering Agents in Patients with Type 2 Diabetes Mellitus: A Narrative Review.

Q3 Medicine

The Journal of the Association of Physicians of India Pub Date : 2025-04-01 DOI:10.59556/japi.73.0923

Sanjay Kalra, Awadhesh Kumar Singh, Sambit Das, Bharadwaja Pendurthi, Shruti Dharmadhikari, Prachi Ahire, Chintan Khandhedia, Neeraj Markandeywar, Amey Mane, Suyog Mehta

{"title":"Sitagliptin as an Add-on Therapy to Other Glucose-lowering Agents in Patients with Type 2 Diabetes Mellitus: A Narrative Review.","authors":"Sanjay Kalra, Awadhesh Kumar Singh, Sambit Das, Bharadwaja Pendurthi, Shruti Dharmadhikari, Prachi Ahire, Chintan Khandhedia, Neeraj Markandeywar, Amey Mane, Suyog Mehta","doi":"10.59556/japi.73.0923","DOIUrl":null,"url":null,"abstract":"<p><p>The burden of type 2 diabetes mellitus (T2DM) is increasing in India, with increasing mortality and morbidity. In India, T2DM management is complicated by the presence of distinct clinical characteristics as well as certain socioeconomic factors of the patient population. These factors affect glycemic control and lead to poorer outcomes, necessitating the use of add-on treatments with safer medications, which can be used over the long term with minimal follow-up. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits the activity of DPP-4, a peptidase that degrades glucagon-like peptide 1 (GLP-1), a glucoregulatory hormone. Sitagliptin enhances glucoregulation in people with T2DM as monotherapy, as well as in combination with other antihyperglycemic drugs, and has a low risk of adverse side effects. This review focuses on assessing the efficacy and safety of sitagliptin as an add-on therapy to other antidiabetic agents and insulin.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 4","pages":"e13-e18"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.73.0923","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The burden of type 2 diabetes mellitus (T2DM) is increasing in India, with increasing mortality and morbidity. In India, T2DM management is complicated by the presence of distinct clinical characteristics as well as certain socioeconomic factors of the patient population. These factors affect glycemic control and lead to poorer outcomes, necessitating the use of add-on treatments with safer medications, which can be used over the long term with minimal follow-up. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits the activity of DPP-4, a peptidase that degrades glucagon-like peptide 1 (GLP-1), a glucoregulatory hormone. Sitagliptin enhances glucoregulation in people with T2DM as monotherapy, as well as in combination with other antihyperglycemic drugs, and has a low risk of adverse side effects. This review focuses on assessing the efficacy and safety of sitagliptin as an add-on therapy to other antidiabetic agents and insulin.

查看原文本刊更多论文

西格列汀作为2型糖尿病患者其他降糖药的附加治疗：一项叙述性综述。

在印度，2型糖尿病（T2DM）的负担正在增加，死亡率和发病率都在增加。在印度，T2DM患者的临床特点和社会经济因素使其管理变得复杂。这些因素影响血糖控制并导致较差的结果，需要使用更安全的药物进行附加治疗，这些药物可以长期使用，随访时间最短。西格列汀是一种二肽基肽酶-4 （DPP-4）抑制剂，可抑制DPP-4的活性，DPP-4是一种降解胰高血糖素样肽1 （GLP-1）的肽酶，是一种血糖调节激素。西格列汀可增强T2DM患者的血糖调节，可单药治疗，也可与其他降糖药物合用，而且不良副作用的风险较低。本综述的重点是评估西格列汀作为其他抗糖尿病药物和胰岛素的附加治疗的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of the Association of Physicians of India Medicine-Medicine (all)

CiteScore

0.80

自引率

0.00%

发文量

509